Printer Friendly

Nycomed buys majority in Chinese Guangdong Techpool Bio-Pharma.


Swiss pharmaceuticals company Nycomed said Monday it has bought a controlling stake of 51.34% in Chinese biopharmaceutical firm Guangdong Techpool Bio-Pharma Co Ltd for an undisclosed sum and in a move to strengthen Chinese activities.

Guangdong Techpool focuses on the development of biologic drugs from natural sources. It has launched a broad-acting trypsin inhibitor, used in sepsis and multiple organ dysfunctions treatment. The company's products are exported to Japan and South Korea.

Shanghai Pharmaceutical Group, the previous majority owner of Guangdong Techpool, will control 40.8% in the company.Country: China, Sector: PharmaceuticalsTarget: Guangdong Techpool Bio-Pharma Co LtdBuyer: Nycomed International Management GmbHVendor: Shanghai Pharmaceutical GroupType: Corporate acquisitionStatus: Closed

COPYRIGHT 2010 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M & A Navigator
Geographic Code:9JAPA
Date:Nov 2, 2010
Previous Article:Canadian Day4 Energy closes German ACI takeover.
Next Article:Advent takes over drilling fluid treatment firm BOS.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters